[{"data":1,"prerenderedAt":209},["ShallowReactive",2],{"drug-mirabegron":3},{"id":4,"schemaVersion":5,"name":6,"category":9,"class":10,"brands":13,"synonyms":17,"formulations":20,"regimens":43,"contraindications":94,"warnings":104,"renal":112,"monitoring":122,"interactions":123,"review":124,"examples":127,"atc":138,"iran":140,"links":152,"populations":169,"usApproval":204},"mirabegron",1,{"fa":7,"en":8},"میرابگرون","Mirabegron","genitourinary-sex-hormones",{"fa":11,"en":12},"آگونیست بتا-۳ آدرنرژیک","Beta-3 adrenergic agonist",[14],{"name":15,"market":16},"Myrbetriq","US",[18,19,7],"myrbetriq","betmiga",[21,35],{"id":22,"form":23,"route":24,"label":25,"concentration":26,"markets":30,"refs":31},"er-25","tablet","oral","25 mg extended-release tablet (swallow whole)",{"amount":27,"unit":28,"perUnit":23,"scored":29},25,"mg",false,[16],[32],{"source":33,"section":34},"fda-myrbetriq","3",{"id":36,"form":23,"route":24,"label":37,"concentration":38,"markets":40,"refs":41},"er-50","50 mg extended-release tablet (swallow whole)",{"amount":39,"unit":28,"perUnit":23,"scored":29},50,[16],[42],{"source":33,"section":34},[44,68],{"id":45,"disease":46,"label":47,"population":50,"type":54,"unit":28,"dose":55,"refs":58,"notes":61},"oab","overactive-bladder",{"fa":48,"en":49},"مثانه بیش‌فعال — بزرگسال: ۲۵ mg یک بار در روز، پس از ۴ تا ۸ هفته تا ۵۰ mg","Overactive bladder — adult: 25 mg once daily, up to 50 mg after 4–8 weeks",{"minAge":51},{"value":52,"unit":53},18,"year","titration",{"dividedDoses":5,"titration":56},{"start":27,"increment":27,"incrementEveryDays":57,"max":39},28,[59],{"source":33,"section":60},"2.2",[62],{"text":63,"refs":66},{"fa":64,"en":65},"همراه سولیفناسین: میرابگرون ۲۵ mg + سولیفناسین ۵ mg.","With solifenacin: mirabegron 25 mg + solifenacin 5 mg.",[67],{"source":33,"section":60},{"id":69,"disease":70,"label":71,"population":74,"type":54,"unit":28,"dose":79,"refs":81,"notes":84},"ndo","neurogenic-bladder",{"fa":72,"en":73},"مثانه نوروژنیک کودک (۳ سال به بالا، ۳۵ kg به بالا) — ۲۵ mg روزانه، پس از ۴ تا ۸ هفته تا ۵۰ mg","Pediatric NDO (≥3 y, ≥35 kg) — 25 mg daily, up to 50 mg after 4–8 weeks",{"minAge":75,"maxAge":77,"minWeightKg":78},{"value":76,"unit":53},3,{"value":52,"unit":53},35,{"dividedDoses":5,"titration":80},{"start":27,"increment":27,"incrementEveryDays":57,"max":39},[82],{"source":33,"section":83},"2.3",[85],{"text":86,"refs":89},{"fa":87,"en":88},"کودک زیر ۳۵ kg: گرانول Myrbetriq (با قرص mg به mg جایگزین نیست). کودک: همراه غذا.","Children \u003C35 kg: Myrbetriq Granules (not interchangeable mg-for-mg). Children: take with food.",[90,92],{"source":33,"section":91},"2.1",{"source":33,"section":93},"2.7",[95],{"id":96,"severity":97,"text":98,"refs":101},"hyper","block",{"fa":99,"en":100},"حساسیت به میرابگرون یا اجزای فرآورده.","Hypersensitivity to mirabegron or excipients.",[102],{"source":33,"section":103},"4",[105],{"text":106,"refs":109},{"fa":107,"en":108},"افزایش فشار خون (پایش)؛ احتباس ادرار با انسداد خروجی مثانه یا آنتی‌موسکارینی؛ آنژیوادم.","Raised blood pressure (monitor); urinary retention with outlet obstruction or antimuscarinics; angioedema.",[110],{"source":33,"section":111},"5",[113],{"egfrBelow":114,"severity":115,"text":116,"refs":119},30,"warn",{"fa":117,"en":118},"eGFR ۱۵ تا ۲۹: حداکثر ۲۵ mg؛ زیر ۱۵: توصیه نمی‌شود.","eGFR 15–29: max 25 mg; \u003C15: not recommended.",[120],{"source":33,"section":121},"2.4",[],[],{"status":125,"reviewer":126,"date":126},"unverified",null,[128,133],{"regimen":45,"formulation":22,"input":129,"expect":132},{"ageYears":130,"weightKg":131},60,70,{"perDose":27,"tabletsPerDoseRounded":5},{"regimen":69,"formulation":22,"input":134,"expect":137},{"ageYears":135,"weightKg":136},12,40,{"perDose":27,"tabletsPerDoseRounded":5},[139],"G04BD12",{"status":141,"forms":142,"refs":147},"registered",[143],{"code":144,"en":145,"fa":146},"51204","MIRABEGRON TABLET, EXTENDED RELEASE ORAL 50 mg","قرص آهسته‌رهش میرابگرون ۵۰ میلی‌گرم",[148],{"source":149,"section":150,"url":151},"darooyab-generic","G-5511\u002FMirabegron","https:\u002F\u002Fwww.darooyab.ir\u002FG-5511\u002FMirabegron",[153,157,161,164,167],{"kind":154,"url":155,"label":156},"fda","https:\u002F\u002Fwww.accessdata.fda.gov\u002Fscripts\u002Fcder\u002Fdaf\u002Findex.cfm?event=overview.process&ApplNo=202611","NDA202611",{"kind":158,"url":159,"label":160},"dailymed","https:\u002F\u002Fdailymed.nlm.nih.gov\u002Fdailymed\u002FdrugInfo.cfm?setid=ba9e9e15-e666-4c56-9271-2e24739cfa2d","FDA Myrbetriq",{"kind":162,"url":163,"label":8},"medlineplus","https:\u002F\u002Fmedlineplus.gov\u002Fdruginfo\u002Fmeds\u002Fa612038.html",{"kind":165,"url":166,"label":139},"who-atc","https:\u002F\u002Fatcddd.fhi.no\u002Fatc_ddd_index\u002F?code=G04BD12",{"kind":168,"url":151,"label":8},"darooyab",{"pregnancy":170,"lactation":179,"pediatric":187,"geriatric":195},{"level":171,"text":172,"quote":175,"refs":176},"caution",{"fa":173,"en":174},"برچسب خطر مشخصی برای بارداری ذکر نکرده یا داده کافی ندارد؛ فقط در صورت لزوم و با نظر پزشک.","Label states no clear risk or has limited data; use only if needed, under medical advice.","Risk Summary There are no studies with the use of MYRBETRIQ\u002FMYRBETRIQ Granules in pregnant women or adolescents to inform a drug-associated risk of major birth defects, miscarriages, or adverse maternal or fetal outcomes.",[177],{"source":33,"section":178},"8.1",{"level":171,"text":180,"quote":183,"refs":184},{"fa":181,"en":182},"برچسب: در شیردهی با احتیاط؛ متن برچسب را ببینید.","Label: use with caution while breastfeeding; see the label text.","Risk Summary There are no data on the presence of mirabegron in human milk, the effects on the breastfed child, or the effects on milk production.",[185],{"source":33,"section":186},"8.2",{"level":171,"text":188,"quote":191,"refs":192},{"fa":189,"en":190},"برچسب برای کودکان شرط، محدودیت سنی یا نکته دارد؛ جمله برچسب در زیر آمده است.","The label has conditions, age limits or notes for children; the label sentence is quoted below.","The safety and effectiveness have been established only for the following pediatric indications: • MYRBETRIQ: Treatment of neurogenic detrusor overactivity (NDO) in pediatric patients 3 years of age and older and weighing 35 kg or more. • MYRBETRIQ Granules: Treatment of neurogenic detrusor overactivity (NDO) in …",[193],{"source":33,"section":194},"8.4",{"level":196,"text":197,"quote":200,"refs":201},"ok",{"fa":198,"en":199},"برچسب: در سالمندان تفاوت یا تنظیم دوز خاصی ذکر نشده.","Label: no specific difference or dose adjustment stated for older adults.","No overall differences in safety or effectiveness were observed between patients younger than 65 years of age and those 65 years of age or older in these studies.",[202],{"source":33,"section":203},"8.5",{"kind":205,"refs":206,"id":156},"NDA",[207],{"source":33,"section":208},"SPL approval \u002F marketing category",1792115189160]